Assistant de documentation des composantes de l’IPI original de 1993 pour le lymphome

État

clinical-review-pending

Version de la méthode

The International Non-Hodgkin's Lymphoma Prognostic Factors Project original 1993 IPI arithmetic, engine original-ipi-1993-v1: one component each for completed age at diagnosis >60 years; original Ann Arbor stage III or IV; externally recorded ECOG performance status 2-4; clinician-verified more than one extranodal disease site; and pretreatment serum total LDH above the same issuing report's local upper limit of normal. Exact age 60, stage I or II, ECOG 0 or 1, zero or one extranodal site, and LDH equal to the same-report ULN each contribute zero. All five verified values from one complete pretreatment baseline are required. ECOG is accepted only as the externally recorded numeric grade, without Karnofsky conversion. The extranodal category is accepted only as externally clinician verified and is never derived from an anatomy checklist. LDH and its same-report local ULN use fixed U/L and exact serum/analyte/reference-limit identities. Output is limited to the raw 0-5 count, five component booleans, and exact entered-value audit; no group, adjective, outcome estimate, diagnosis, prognosis, treatment, disposition, or recommendation is supplied.

Population

Adults age 18 years or older with histologically confirmed newly diagnosed, previously untreated aggressive non-Hodgkin lymphoma, for whom a treating specialist independently selected the original 1993 IPI. The historical source comprised 3,273 adult records from doxorubicin-containing phase II and III trials conducted in 1982-1987; 2,031 records had complete data and were divided into a 1,385-patient training set and 646-patient validation set. The Working Formulation, Kiel, and Rappaport histology classifications used by the source are obsolete and the source predates rituximab. Current-era transport must be explicitly acknowledged. Completed age at diagnosis, original Ann Arbor stage, externally recorded numeric ECOG grade, clinician-verified extranodal site-count category, and serum total LDH with the same issuing report's local ULN must all be explicit, complete, verified, and from one pretreatment presentation before prephase or therapy.

Limites et exclusions

Pediatric patients; Hodgkin lymphoma; indolent lymphoma; primary CNS lymphoma or another setting requiring a disease-specific index; relapsed or refractory disease; post-treatment restaging; or use to establish a diagnosis, histology, index selection, or source applicability. · Missing, unknown, inferred, imputed, defaulted, carried-forward, mixed-timepoint, later, post-prephase, or post-treatment inputs; an inferred Ann Arbor stage; Karnofsky-to-ECOG or other performance-status conversion; an anatomy-derived extranodal count; or an unverified stage, ECOG grade, extranodal category, timing, source, or identity. · LDH without its same issuing report local ULN; a universal absolute LDH threshold; LDH or ULN in unsupported units; different reports or timepoints; non-serum or non-total-LDH values; a ratio entered in place of source measurements; or unverified analyte, specimen, report, reference-limit, or unit identity. · Age-adjusted IPI; revised IPI grouping; NCCN-IPI; CNS-IPI; FLIPI or FLIPI2; MIPI; PIT or PINK; Hodgkin lymphoma IPS; any group, risk adjective, cutoff, survival or mortality estimate, probability, individual prognosis, diagnostic conclusion, CNS interpretation, treatment, transplant, disposition, recommendation, management, or care decision.

• https://pubmed.ncbi.nlm.nih.gov/8141877/
• https://doi.org/10.1056/NEJM199309303291402
• https://pubmed.ncbi.nlm.nih.gov/25113753/
• https://ecog-acrin.org/resources/ecog-performance-status/
• https://doi.org/10.1002/hem3.70207

Outil importé de la bibliothèque PharmaTek de MDose. Aucune date de révision clinique indépendante n’est documentée dans cette version.

Bibliothèque source

PharmaTek · MDose

Version importée

4b66536936ed

État de publication

Révision clinique en cours